Summary
Adjuvant treatment of stage II colon cancer remains an issue of controversy. Though there is evidence indicating that adjuvant therapy is associated with a limited survival benefit, large clinical trials published so far did not provide enough evidence to regard adjuvant therapy of stage II colon cancer as standard of care. The ultimate clinical decision should be based on the presence of high-risk prognostic features, the evidence supporting treatment, the anticipated side effects and morbidity of treatment as well as patient preferences. Considering all these circumstances, regimen containing oxaliplatin together with 5-FU/leukovorin may be regarded as standard therapy. Stage II rectal cancer represents an excellent example for the need of close collaboration between both surgeons and medical oncologists together with radiation oncologists. The combination of radiotherapy and chemotherapy given in the neoadjuvant or adjuvant setting can be regarded as standard therapy. The potential benefit of the addition of oxaliplatin is currently under investigation. The goal of ongoing studies is to investigate whether combination of chemotherapy with therapeutic antibodies such as cetuximab or bevacizumab will become standard of care in the adjuvant setting.
Similar content being viewed by others
References
Benson A, Schrag D, Somerfield M, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22: 3408–3419, 2004
Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol, 22: 3395–3407, 2004
Kerr D, Barnwell J, Hills R, et al. QUASAR Collaborative Group: a randomized study of adjuvant chemotherapy (CT) vs observation in predominately stage II colorectal cancer. Presented at the 2004 Congress of the European Society of Clinical Oncology. Ann Oncol, 15 (Suppl 3): 2004 (abstr 43IN)
QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet Oncol, 370: 2020–2029, 2007
André T, Boni C, Mounedji-Boudiaf L, Navarro M, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. NEJM, 350: 2343–2351, 2004
de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years (abstract 3501). J Clin Oncol, 23(16S): 246s, 2005
Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25: 2156–2158, 2007
Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. NEJM, 352: 2696–2704, 2005
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. NEJM, 324: 709–715, 1991
Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst, 80(1): 21–29, 1988
Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex and local control – final report of intergroup 0114. J Clin Oncol, 20: 1744–1750, 2002
Frykholm G, Glimelius B, Pahlma L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum, 36(6): 564–572, 1993
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM, 350: 2335–2342, 2004
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM, 351: 337–345, 2004
Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 15: 3408–3419, 2004
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zwierzina, H. Adjuvant therapy of stage II colorectal cancer – who will benefit from treatment?. memo 1, 75–77 (2008). https://doi.org/10.1007/s12254-008-0037-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0037-y